Compare Novo Nordisk A/S (NVO) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Global X Uranium ETF — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Global X Uranium ETF trades at $40.5. The key difference: Novo Nordisk A/S pays a 3.63% dividend while Global X Uranium ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| NVO | URA | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $71.70 | $61.81 |
52-Week Low | $35.29 | $36.45 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
